IBT's principal, Dr. M. Javad Aman, has a long track record of scientific and developmental accomplishments in vaccine and immunotherapeutics development for infectious diseases, including highly productive work during their tenures at USAMRIID. The company has a successful track record in early-stage discovery work for viral and bacterial diseases, including discovery of antimicrobial small molecule inhibitors, development of antibody therapeutics for Marburg virus (collaboration with Scripps), development of a panfilovirus VLP-based vaccine (NIAID) as well as a second generation filovirus vaccine (Collaboration with University of Texas) and numerous other projects. Over the past four years IBT has secured and managed over $35M in government grants and contracts.
Dr. M. Javad Aman received his Ph.D. in molecular immunology at the University of Mainz, Germany. Following a research fellowship at the NIH and an academic position at the University of Virginia, he worked as a lead scientist at USAMRIID for 7 years prior to founding Integrated BioTherapeutics (IBT). His research at USAMRIID resulted in development of a vaccine for Ebola and Marburg viruses, now in late pre-clinical development. His work has also led to small molecule inhibitors of filoviruses currently in development by Functional Genetics Inc. under a DTRA funded program, as well as human therapeutic antibodies for Staphylococcal Enterotoxin B, currently funded by NIAID and under development at IBT. Dr. Aman is currently the President and Chief Scientific Officer at IBT and serves as PI on multiple government funded contracts and grants. He has authored over 60 publications in international journals and is the inventor on multiple U.S. and international patents and patent applications.